[go: up one dir, main page]

WO2016080691A1 - Composition pharmaceutique comprenant des extraits de symplococs chinesis et astragalus membranaceus pour prévenir et traiter l'arthrite, et son procédé de préparation - Google Patents

Composition pharmaceutique comprenant des extraits de symplococs chinesis et astragalus membranaceus pour prévenir et traiter l'arthrite, et son procédé de préparation Download PDF

Info

Publication number
WO2016080691A1
WO2016080691A1 PCT/KR2015/011973 KR2015011973W WO2016080691A1 WO 2016080691 A1 WO2016080691 A1 WO 2016080691A1 KR 2015011973 W KR2015011973 W KR 2015011973W WO 2016080691 A1 WO2016080691 A1 WO 2016080691A1
Authority
WO
WIPO (PCT)
Prior art keywords
astragalus
extract
pharmaceutical composition
arthritis
mixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2015/011973
Other languages
English (en)
Korean (ko)
Inventor
최수임
김재윤
최종길
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YD LIFE SCIENCE CO Ltd
Original Assignee
YD LIFE SCIENCE CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YD LIFE SCIENCE CO Ltd filed Critical YD LIFE SCIENCE CO Ltd
Priority to CN201580050608.8A priority Critical patent/CN106794212A/zh
Publication of WO2016080691A1 publication Critical patent/WO2016080691A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)

Definitions

  • the present invention relates to a pharmaceutical composition for the prevention or treatment of arthritis, including a Stink bug extract and Astragalus extract, and a method of manufacturing the same.
  • Arthritis is a representative of cartilage-related diseases, which are roughly classified into rheumatoid arthritis and degenerative arthritis (osteoarthritis), and knee joint cartilage is frequently found in traffic accidents or excessive exercise. At present, there are about one million arthritis patients in Korea, and women are more than twice as many as men, especially menopausal women (Belmonte-S. MA et al; Arthritis Rheum, 30, pp 1214-). 1225, 1987).
  • Osteoarthritis is a disease in which local degenerative changes occur as the articular cartilage wears off, also called osteoarthritis or osteoarthritis. Osteoarthritis is a representative degenerative disease that is closely related to aging. About 10 to 15% of the entire population suffers from osteoarthritis. In particular, about 60 to 80% of the elderly aged 65 or older suffer from osteoarthritis. The causes of degenerative arthritis are deeply related to senility and excessive weight, and appear more and more severely in women as they age (Oliver, JE et al; Scand J Rheumatol, 35, pp 169-174, 2006). Early symptoms appear as pain, as one or two joints swell with stiffness, and prolonged periods lead to joint deformation.
  • cartilage protection agent only serves to protect joints by nourishing chondrocytes or alleviating shock.
  • steroidal agents have side effects that can lead to osteoporosis, high blood pressure, diabetes, etc., due to loss of calcium when taken for a long time. Therefore, in most cases, the drug is used only for the purpose of reducing pain, and permanent arthroplasty is mainly performed, but there are no drugs or surgical methods that provide a fundamental therapeutic effect.
  • the stink wood ( Symplocos chinensis for. Pilosa (Nakai) Ohwi) is a species of Symplocaceae , distributed in China, Japan and India. It is a deciduous shrub that grows in mountains and fields of Korea and grows to 1-3m in height. The leaves are regenerated, ovate or long oval ovate with pointed ends, usually with small jagged edges but sometimes not clear, the surface is dark green, without hairs, light green on the back and without hairs. Fruits are 8mm long, oval, ripen in September. Cone inflorescence is 4 ⁇ 8cm long, hangs at the end of new branches, hairs are in the flower garden, petals are long oval and bursts to the side. The flower is 8-10mm in diameter and blooms white in May. The petals are long oval, with a lot of stamens, and can be enjoyed for about a full time with a subtle scent.
  • Astragalus membranaceus (Fisch) Bunge Is a perennial herbaceous plant belonging to the head family, with a deep, long, stick-like, slightly woody. Stems are upright, branched a lot at the top, smooth, glossy, or covered with a little hair.
  • the main components of Astragalus are polysaccharides and saponins, in addition to sucrose, beta-sitosterol, calycosin, formonetin and beta-amino Butyric acid ( ⁇ -aminobutyric acid) is contained.
  • the physiological activity of Astragalus has been reported to enhance cellular and humoral immunity, antioxidant, anti-aging, anti-inflammatory, tonic, diuretic, blood pressure lowering.
  • Hwanggi is a medicine that protects the human body from a long time ago.
  • many ingredients such as Hwanggigunjungtang, Jeopjeondaebotang, Hwanggigi Geomultang, and Banggiwanggigitang have been used as herbal medicines after ginseng.
  • Banggiwanggigitang has been used as herbal medicines after ginseng.
  • Salvia (Salvia miltiorrhiza BUNGE) is distributed as a perennial of dicotyledon plants currency neck Lamiaceae in China, Korea (North Gyeongsang, Gangwon province), Japan. It is 40 ⁇ 80 cm high and covered with yellowish white soft hairs and hairs.
  • the medicinal herb is a dried perennial herb, the root of which is short and rough, and the apical remains are usually attached to the stem. Roots are long columnar, sometimes divided into one or two or several, 8-25 cm long, 3-10 mm in diameter. It is known that sweet ginseng contains tanshinone I, IIA, IIB, 15,16-dihydrotanshinone I, and cryptotanshinone.
  • Dansam has the effect of vasodilation, antibacterial, sedation, analgesic effect, anti-cancer experiments have been shown to inhibit the respiration (energy metabolism) of cancer cells and inhibit the degradation of sugar fermentation.
  • Dansam is a widely used medicinal herb for liver cirrhosis, allergic purpura, coronary arteriosclerosis, and uterine disease.
  • the present invention is to provide a composition and a method for producing the same, which can effectively prevent or treat arthritis, including a mixed extract of Stink bug tree and Astragalus.
  • the present invention is to provide a pharmaceutical composition for the prevention or treatment of arthritis that does not have toxicity or side effects even if taken for a long time or directly administered in the human body.
  • a pharmaceutical composition for the prevention or treatment of arthritis comprising a Stinkthorn tree extract and Astragalus extract as an active ingredient.
  • the hemipphyllum extract and Astragalus extract may be extracted from bilberry and astragalus with water or C 1-4 alcohol.
  • the stink bug tree and Astragalus may be mixed in a weight ratio of 5: 1 to 1: 5.
  • the stink bug tree and Astragalus may be mixed in a weight ratio of 1: 3 to 5.
  • composition may further comprise the extract of Salvia.
  • the hemipphyllum extract, Astragalus extract, and Dansam extract may be extracted from hemip tree, Astragalus and Salvia sinensis with water or C 1-4 alcohol.
  • the stink bug tree, Astragalus and Dansam may be mixed in a weight ratio of 1 to 3: 1 to 3: 1 to 3.
  • the stink bug tree, Astragalus and Dansam may be mixed in a weight ratio of 1: 1: 1 to 3.
  • preparing a herbal medicine comprising a stiletto wood and Astragalus
  • It provides a method for producing a pharmaceutical composition for preventing or treating arthritis, comprising extracting by adding water or C 1-4 alcohol to the prepared herbal medicines.
  • the stink bug tree and Astragalus may be mixed in a weight ratio of 5: 1 to 1: 5.
  • the stink bug tree and Astragalus may be mixed in a weight ratio of 1: 3 to 5.
  • the herbal medicine may further comprise a salvia.
  • the stink bug tree, Astragalus and Dansam may be mixed in a weight ratio of 1 to 3: 1 to 3: 1 to 3.
  • the stink bug tree, Astragalus and Dansam may be mixed in a weight ratio of 1: 1: 1 to 3.
  • water or C 1-4 alcohol may be added in an amount of 5 to 20 times the weight of the herbal medicine.
  • composition provided by the present invention is effective in preventing and treating arthritis, including the stink bug extract and Astragalus extract.
  • the extract used in the present invention is a natural derived material, there is no toxicity or side effects even if taken in the long term or directly administered in the human body.
  • Figure 2 is a graph showing the results of MMP-3 mRNA expression analysis in SW1353 chondrocytes according to the treatment of each composition in Experimental Example 3.
  • Figure 3 shows a photograph of articular cartilage tissue after the treatment of each composition in Experimental Example 4.
  • a pharmaceutical composition for the prevention or treatment of arthritis comprising a Stinkthorn tree extract and Astragalus extract as an active ingredient.
  • the present invention relates to a pharmaceutical composition for the prevention or treatment of arthritis, and more specifically, the hemipteran extract and Astragalus extract as active ingredients.
  • the hemipteran extract and Astragalus extract may be obtained by extracting the whole plant, or as part of the plant, by extracting roots, leaves, flowers, branches, stems or fruits. Preferably, it may be obtained by extracting at least one of the leaves, branches and roots of each stink bug and Astragalus.
  • the stink bug extract and Astragalus extract used in the present invention are not only toxic as a natural derived material, but also inhibit the synthesis of inflammatory substance free and matrix-destructive substances in cartilage cells and tissues of joints, and prevent pathologies such as pain and swelling of arthritis. It exhibits activity that inhibits progression, thereby preventing or treating arthritis without side effects.
  • the hemipteran extract and Astragalus extract may be a mixture obtained by separately extracting hemipteran and astragalus, but preferably the mixed herbal medicine of the hemiprouswood and Astragalus was extracted using water or C 1-4 alcohol. It may be.
  • the hemipphyllum extract and Astragalus extract is preferably extracted from the medicinal herb mixed with hemipphyllum and Astragalus in a weight ratio of 5: 1 to 1: 5, it is preferable to obtain a mixed extract with a high extraction yield, and more preferably Extracting from the herbal medicine mixed with wood and Astragalus in a weight ratio of 1: 3-5 may further enhance the prevention or treatment of arthritis.
  • a Salvia extract in order to further enhance the prophylactic or therapeutic effect of the arthritis as described above may further comprise a Salvia extract.
  • the extract may also be a mixture of extracts obtained by extracting the only dansam ginseng extract and Astragalus extract, preferably using a mixed herbal medicine of stink bugs, Astragalus and Dansam using water or C 1-4 alcohol It may be extracted.
  • the hemipphyllum extract, Astragalus extract and Dansam extract can be obtained from the medicinal herb mixed with hemipphyrus, Astragalus and Salvia extract in a weight ratio of 1 to 3: 1 to 3: 1 to 3 can obtain a mixed extract with a high extraction yield It is preferable, and more preferably, extracting from the herbal medicine mixed with stink bug tree, Astragalus and Dansam in a weight ratio of 1: 1: 1 to 3 can significantly increase the prevention or treatment effect of arthritis.
  • prevention in the present invention means any action that inhibits inflammation or delays the onset by the administration of the composition
  • treatment means all the symptoms that improve or beneficially change the symptoms caused by the administration of the composition It means an act.
  • the pharmaceutical composition may further include a suitable carrier, excipient or diluent according to a conventional method.
  • Carriers, excipients and diluents that may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, methylhydroxy benzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like can be used, but are not limited thereto.
  • compositions according to the present invention may be formulated in the form of oral dosage forms, external preparations, suppositories, or sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to a conventional method.
  • sterile injectable solutions such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to a conventional method.
  • it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and the like.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, in the pharmaceutical composition of the present invention.
  • excipients such as starch, calcium carbonate, in the pharmaceutical composition of the present invention.
  • Sucrose, lactose, gelatin and the like can be mixed and prepared.
  • lubricants such as magnesium stearate, talc can also be used.
  • Liquid preparations for oral use include suspensions, solvents, emulsions, and syrups, and include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. Can be.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • Routes of administration of the pharmaceutical compositions according to the invention are not limited to these, but are oral, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical , Sublingual or rectal. Oral or parenteral release is preferred.
  • parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intramuscular, intrasternal, intradural, intralesional and intracranial injection or infusion techniques.
  • the pharmaceutical compositions of the invention may also be administered in the form of suppositories for rectal administration.
  • the pharmaceutical composition of the present invention is dependent on a number of factors, including the activity, age, weight, general health, sex, formulation, time of administration, route of administration, rate of release, drug combination and severity of the particular disease to be prevented or treated, of the specific compound employed.
  • the dosage of the pharmaceutical composition may vary depending on the patient's condition, weight, extent of disease, drug form, route of administration and duration, and may be appropriately selected by those skilled in the art and may be 0.0001 to 50 mg / day. It may be administered at kg or 0.001 to 50 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • the pharmaceutical compositions according to the invention may be formulated as pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions.
  • the present invention relates to a method for preparing a pharmaceutical composition for preventing or treating arthritis, and more particularly, preparing a herbal medicine including stink bug and astragalus; And extracting water or C 1-4 alcohol by adding the prepared herbal medicine.
  • the stink bugs and coriander contained in the herbal medicine prepared here are preferably mixed extracts at a high extraction yield with a weight ratio of 5: 1 to 1: 5, and more preferably, stink bugs and coriander are 1: 3 to Using a mixture of 5 weight ratios can significantly increase the prophylactic or therapeutic effect of arthritis.
  • a herbal medicine in order to further increase the effect of preventing or treating arthritis, as a herbal medicine, may further comprise a dansam ginseng with stink bug trees and Astragalus.
  • the hemip tree, Astragalus and Salvia ginseng contained in the herbal medicine prepared here are preferably mixed extracts at a high extraction yield, which are mixed in a weight ratio of 1 to 3: 1 to 3: 1 to 3, and more preferably Using a mixture of Astragalus and Danseng in a weight ratio of 1: 1: 1 to 3 can significantly increase the prevention or treatment of arthritis.
  • the water or C 1-4 alcohol is preferably added in an amount of 5 to 20 times the weight of the herbal medicine.
  • the extraction step in the present invention is preferably carried out for 24 to 72 hours at a temperature of 15 ⁇ 30 °C.
  • the present invention may further comprise the step of obtaining a powdery extract by additionally performing a process such as vacuum distillation, freeze drying or spray drying to the extract obtained as needed.
  • a process such as vacuum distillation, freeze drying or spray drying
  • Salvia extract optionally included in the mixed extract of Stink bug and Astragalus obtained as described above in the present invention is not only toxic as a natural derived material, but also inhibits the synthesis of inflammatory substance free and substrate-destructive substances in cartilage cells and tissues of joints. And inhibiting pathological progression such as pain and swelling of arthritis, thereby preventing or treating arthritis without side effects.
  • diluents may be added to the extract obtained as needed to prepare a pharmaceutical composition for the prevention or treatment of arthritis.
  • lubricants binders, disintegrants, buffers, dispersants, surfactants, coloring agents, fragrances or sweeteners, etc.
  • disintegrants buffers, dispersants, surfactants, coloring agents, fragrances or sweeteners, etc.
  • surfactants coloring agents, fragrances or sweeteners, etc.
  • the 'yield' may be calculated by the following equation.
  • Example 1 As shown in Table 1, the extract of the mixture of Stink bug tree and Astragalus in the weight ratio of 5: 1 to 1: 5 in Examples 1 to 9 to obtain a mixed extract of the Bilberry and Astragalus with a high yield of 18% or more. It can be seen that, in particular, in Example 1 using a mixture of stink bug and Astragalus in a weight ratio of 1: 1, it can be seen that a mixed extract was obtained with a very high yield of 22.2%.
  • Example 10 to 17 extract of the mixture of Astragalus, Stink bug, and Dansam in a weight ratio of 1 to 3: 1 to 3: 1 to 3, the mixed extract of the Stink bug, Astragalus and Dansam with a high yield of 28% or more It can be seen that the obtained, especially in Example 12 and 14 stinkwood, Astragalus and Salvia ginseng were mixed at a weight ratio of 1: 1 to 2: 3, respectively, as a result of which a mixed extract was obtained with a very high yield of 38% or more. Can be.
  • SW1353 chondrosarcoma cell line was purchased from ATCC (HTB-94, Rockville, MD, USA).
  • DMEM Dubcco's Modified Eagle Medium
  • FBS Fetal bovine serum
  • FBS Fetal bovine serum
  • 1456396 Fetal bovine serum
  • Gibco ® Life Technologies Fetal bovine serum
  • SW1353 cells incubated in 96 well plates with 1 X 10 5 cells were treated with the concentrations of 25 ⁇ g / ml, 50 ⁇ g / ml, 100 ⁇ g / ml and 200 ⁇ g / ml for each of the mixed extracts obtained in Examples 1 to 17. After 24 hours incubation in 37 °C incubator was confirmed the cell viability. At this time, the cell viability of SW1353 cells was measured by MTT (methylthiazol tetrazolium bromide) assay, and the results were calculated using the 10% fetal bovine serum (FBS) treated group as a control, and the survival rate (%) was calculated. .
  • MTT methylthiazol tetrazolium bromide
  • the survival rate of the SW1353 cells treated with the mixed extracts of Examples 1 to 17 at the concentrations of 25 ⁇ g / ml, 50 ⁇ g / ml, 100 ⁇ g / ml and 200 ⁇ g / ml were all controls.
  • the composition according to the present invention does not directly affect cell death.
  • the cell culture medium no treatment
  • the extract after IL-1 ⁇ treatment The results of the cell culture solution (IL-1 ⁇ 20 ng / mL) not treated as shown in FIG. 1 were used as a control.
  • MMP-1 and MMP were both treated with a single extract of Comparative Examples 1 to 3 and treated with a mixed extract of Examples 1 to 17 as compared with the case of treating only IL-1 ⁇ . -3, the production amount of MMP-13 can be seen to decrease.
  • RNA expression in cells was performed on matrix metalloproteinases (MMP) -1 and MMP-3. PCR products were electrophoresed using 2.0% agarose gel and stained with ethidium bromide to measure the mRNA expression. The results are shown in FIG. 2.
  • the cell culture medium no treatment
  • the extract after IL-1 ⁇ treatment The results of the cell culture solution (IL-1 ⁇ 20 ng / mL) not treated as shown in FIG. 2 were used as a control.
  • the primers and reaction conditions used in the experiment are as follows.
  • MMP-1 (F) AGTGACTGGGAAACCAGATGA / (R) CGTCTTGGCAAATCTGGCCTGTAA (Annealing Temperature: 57 ° C, 35 cycles)
  • MMP-3 (F) ATTCCATGGAGCCAGGCTTTC / (R) CATTTGGGTCAAACTCCACTGTG (57 ° C, 35 cycles)
  • PCR resulted in 2% After electrophoresis for 30 minutes on the agarose gel, the mRNA band was observed by UV transilluminator (UVP ChemiDoc-It, USA) and the band was quantified using VisionWorksLS (version 7.1) program.
  • MMP-1 and MMP-3 which are cartilage matrix collagen degrading enzymes
  • mice Male Wistar rats (Orient-bio Inc., Korea) of about 120-140 g were purchased and adapted for one week in a clean animal breeding room (temperature 23 ⁇ 1 °C, humidity 55 ⁇ 5%) and used for the experiment. Feed and drinking water were taken freely during the experiment. Osteoarthritis induction model using rat It was induced according to the method of Bove et al. (2003). Monosodium iodoacetate (MIA) (Sigma-aldrich, USA) solution was prepared at a concentration of 5 mg / mL in saline for injection. Anesthesia was injected by intramuscular injection of Zoletile: Rumpun (2: 1) at the start of the test (D0), and the entire front right knee was disinfected.
  • MIA Monosodium iodoacetate
  • MIA solution (1 mg / 50 ⁇ l) was injected into the knee joint and hemilton syringe (26 gauge). ), And accurately injected into the center of the knee cartilage.
  • the normal group was injected into the knee joint by the same method of physiological saline for injection.
  • each sample was orally administered by dividing the body into six groups of eight animals with weight and incidence.
  • the normal group (G1 group, normal group) was orally administered only distilled water
  • the control group (G2 group, MIA treatment group, arthritis induction control group) was orally administered distilled water after MIA induction.
  • the positive control drug group and the treatment group were each treated with arthritis therapeutic agent, Insjung (G3 group, 200 mg / kg), and Comparative Examples 1 to 3 of Astragalus, Stink bug, and Salvia Militiorrhiza extract (G4-G6 group, 200 mg / kg), Example 1 Extracts obtained from (G7 group), Example 10 (G8 group) and Example 11 (G9 group) were dissolved in distilled water and administered orally once a day for 2 weeks.
  • arthritis therapeutic agent Insjung
  • Comparative Examples 1 to 3 of Astragalus, Stink bug, and Salvia Militiorrhiza extract G4-G6 group, 200 mg / kg
  • Example 10 (G8 group) and Example 11 (G9 group) were dissolved in distilled water and administered orally once a day for 2 weeks.
  • histopathological items include subchondral bone change, chondrocyte necrosis, cartilage erosion, osteoplasia and cartilage cleft according to the method of Guzman et al. (2003). ) To 0 to 5 points per item. Speculum scores are shown as mean and standard deviation, and the results were tested using the nonparametric Kruskal-Wallis test. When the significance level was p ⁇ 0.05, the Kruskal-Wallis test showed statistical significance between Dunn's multiple comparision test. Statistical processing between the groups was performed using GraphPad PRISM® Version 4.0 (GraphPad Software, USA), the results are shown in Table 2 below.
  • arthritis-induced control group (G2 group) was 16.17 ⁇ 3.37, and JOS group (G3 group) was 12.43 ⁇ 2.23
  • Astragalus extract administered group (G4 group) showed the best effect with a score of 9.86 ⁇ 1.35, but when the mixed extracts of Examples 1, 10 and 11 were used, the scores were 9.50 ⁇ 4.59, respectively. 9.00 ⁇ 2.74 and 8.20 ⁇ 2.95 were found to have a much better therapeutic effect of arthritis than a single extract.
  • the osteoarthritis-induced G2 group was observed arthritis damage as compared to the normal group G1 group, a single extract of Astragalus extract, Hemiphyllum extract and Dansam extract, and a mixed extract thereof for 2 weeks Efficacy of anti-arthritis was confirmed in the G4 to G9 groups administered orally.
  • G7 group to G9 group orally administered a mixed extract was found to be significantly better efficacy than G4 group, G5 group and G6 group orally administered a single extract.
  • the present invention relates to a pharmaceutical composition for the prevention or treatment of arthritis, including a Stink bug extract and Astragalus extract, and a method of manufacturing the same.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant des extraits de Symplococs chinesis et Astragalus membranaceus pour prévenir et traiter l'arthrite, et un procédé de préparation de celle-ci. Plus particulièrement, la présente invention concerne une composition pharmaceutique comprenant, en tant que substances actives, des extraits de Symplococs chinesis et Astragalus membranaceus pour prévenir ou traiter l'arthrite, et un procédé de préparation de la composition comprenant les étapes de : préparation d'herbes médicinales comprenant Symplococs chinesis et Astragalus membranaceus; et ajout d'eau ou d'un alcool en C1-4 aux herbes médicinales préparées afin d'extraire celles-ci.
PCT/KR2015/011973 2014-11-18 2015-11-09 Composition pharmaceutique comprenant des extraits de symplococs chinesis et astragalus membranaceus pour prévenir et traiter l'arthrite, et son procédé de préparation Ceased WO2016080691A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201580050608.8A CN106794212A (zh) 2014-11-18 2015-11-09 包含山矾以及黄芪的提取物的关节炎的预防或治疗用药学组合物及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140160920A KR101483647B1 (ko) 2014-11-18 2014-11-18 노린재나무 및 황기의 추출물을 포함하는 관절염의 예방 또는 치료용 조성물 및 그 제조방법
KR10-2014-0160920 2014-11-18

Publications (1)

Publication Number Publication Date
WO2016080691A1 true WO2016080691A1 (fr) 2016-05-26

Family

ID=52590737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/011973 Ceased WO2016080691A1 (fr) 2014-11-18 2015-11-09 Composition pharmaceutique comprenant des extraits de symplococs chinesis et astragalus membranaceus pour prévenir et traiter l'arthrite, et son procédé de préparation

Country Status (3)

Country Link
KR (1) KR101483647B1 (fr)
CN (1) CN106794212A (fr)
WO (1) WO2016080691A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278444A (zh) * 2018-06-12 2020-06-12 碧睿制药有限公司 含有dna片段混合物及基质金属蛋白酶生成抑制剂的用于预防及治疗关节炎的组合物
CN111328614A (zh) * 2020-03-24 2020-06-26 遵义市林业科学研究所 山矾树种-老鼠矢播种苗与埋条两段育苗方法
CN112924572A (zh) * 2021-01-21 2021-06-08 上海中医药大学 一种防己黄芪汤的体内外多成分分析方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200086207A (ko) 2019-01-08 2020-07-16 서울대학교산학협력단 노린재나무 속 식물 추출물 또는 이로부터 분리한 화합물을 유효성분으로 포함하는 당뇨 관련 질환의 예방 또는 치료용 조성물
CN112022951A (zh) * 2020-08-11 2020-12-04 吉林大学 一种包含黄芪的提取物的关节炎的预防或治疗用药学组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100589050B1 (ko) * 2004-11-23 2006-06-14 인하대학교 산학협력단 황기 추출물 및 그로부터 분리한 이소플라보노이드계화합물을 유효성분으로 하는 관절염 예방 및 치료용 조성물
KR20100042337A (ko) * 2008-10-16 2010-04-26 변정윤 류머티스관절염 치료제 생약제 조성물 및 그 치료제 제조방법
KR20100080972A (ko) * 2009-01-05 2010-07-14 김선일 나무수액 발효물과 그 이용방법.
KR101132040B1 (ko) * 2011-04-18 2012-04-02 (주)프론트바이오 노린재 나무 또는 노린재 나무 잎 추출물을 포함하는 진통제 또는 신경병증성 통증치료제의 조성물
KR20130042537A (ko) * 2013-04-17 2013-04-26 재단법인 제주테크노파크 항히스타민제 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080011921A (ko) * 2006-08-01 2008-02-11 퓨리메드 주식회사 단삼추출물을 포함하는 자가면역질환치료제
CN101933576B (zh) * 2010-09-21 2012-10-03 杨润菊 苦荞麦饭的制作方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100589050B1 (ko) * 2004-11-23 2006-06-14 인하대학교 산학협력단 황기 추출물 및 그로부터 분리한 이소플라보노이드계화합물을 유효성분으로 하는 관절염 예방 및 치료용 조성물
KR20100042337A (ko) * 2008-10-16 2010-04-26 변정윤 류머티스관절염 치료제 생약제 조성물 및 그 치료제 제조방법
KR20100080972A (ko) * 2009-01-05 2010-07-14 김선일 나무수액 발효물과 그 이용방법.
KR101132040B1 (ko) * 2011-04-18 2012-04-02 (주)프론트바이오 노린재 나무 또는 노린재 나무 잎 추출물을 포함하는 진통제 또는 신경병증성 통증치료제의 조성물
KR20130042537A (ko) * 2013-04-17 2013-04-26 재단법인 제주테크노파크 항히스타민제 조성물

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278444A (zh) * 2018-06-12 2020-06-12 碧睿制药有限公司 含有dna片段混合物及基质金属蛋白酶生成抑制剂的用于预防及治疗关节炎的组合物
CN111328614A (zh) * 2020-03-24 2020-06-26 遵义市林业科学研究所 山矾树种-老鼠矢播种苗与埋条两段育苗方法
CN112924572A (zh) * 2021-01-21 2021-06-08 上海中医药大学 一种防己黄芪汤的体内外多成分分析方法

Also Published As

Publication number Publication date
CN106794212A (zh) 2017-05-31
KR101483647B1 (ko) 2015-01-16

Similar Documents

Publication Publication Date Title
WO2016080691A1 (fr) Composition pharmaceutique comprenant des extraits de symplococs chinesis et astragalus membranaceus pour prévenir et traiter l'arthrite, et son procédé de préparation
WO2012050396A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du foie
WO2010137846A2 (fr) Composition pour accroître de la biodisponibilité de la saponine
WO2014058142A1 (fr) Composition pharmaceutique contenant un extrait d'aster glehni en tant que principe actif pour la prévention et le traitement de l'obésité et de troubles métaboliques
WO2010058926A2 (fr) Composition pharmaceutique contenant un extrait de gingembre ou du shogaol
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
WO2012050397A2 (fr) Composition pharmaceutique comprenant un extrait de plantes médicinales pour la prévention ou le traitement du cancer du rein
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
WO2021040416A1 (fr) Composition pharmaceutique pour prévenir ou traiter la perte osseuse induite par des maladies métaboliques osseuses, comprenant un extrait d'artemisia scoparia en tant que principe actif
WO2017018791A1 (fr) Extrait de fruit de ginseng contenant un ingrédient fonctionnel préventif contre les dommages hépatiques dus à l'alcool et procédé de préparation de celui-ci
WO2011019153A2 (fr) Composition pour la prévention ou le traitement de l’arthrite, contenant un extrait d’un mélange médicinal à base de plantes de schisandra chinensis baillon, scutellaria baicalensis et kalopanax pictus nakai en tant qu’ingrédient actif
KR101103481B1 (ko) 한약재 추출물을 유효성분으로 함유하는 자궁근종 치료용 약학조성물
WO2010123179A1 (fr) Préparation pharmaceutique de prévention ou de traitement de l'arthrose contenant des extraits de graines de vitis vinifera
WO2022211396A1 (fr) Composition pharmaceutique incluant un extrait de salvia plebeia r. br. ou un composé dérivé de celui-ci en tant que principe actif pour la prévention ou le traitement de la dystrophie musculaire
WO2019124757A1 (fr) Composition pour la prévention, le traitement ou l'amélioration d'une maladie de la prostate comprenant des extraits d'acanthopanacis cortex, de phragmitis rhizoma, et de pinus densiflora en tant que principe actif
WO2022220458A1 (fr) Composition comprenant un extrait de fruit immature d'aurantii comme ingrédient actif pour la prévention ou le traitement d'un symptôme de la climatère masculin
KR100836559B1 (ko) 염증성 질환 치료 및 예방에 유용한 녹제초 추출물
KR102748815B1 (ko) 돌외 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물
CN113082085A (zh) 一种管花肉苁蓉提取物及其制备方法
WO2016114621A2 (fr) Composition pour la prévention ou le traitement de maladies métaboliques osseuses comprenant un extrait combiné de schisandra chinesis, d'eucommiae cortex et de lycium chinense comme ingrédient efficace
CN104523849B (zh) 一种杜仲环烯醚萜的药物组合物及其应用
WO2020111652A1 (fr) Composition permettant de prévenir ou de traiter des maladies osseuses métaboliques ou des symptômes de la ménopause
WO2010067953A2 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'ostéoporose contenant des extraits de graine de vitis vinifera
WO2023128197A1 (fr) Composition pour soulager, prévenir ou traiter la sarcopénie, comprenant un extrait de germe de cacahuète de jeju udo en tant que principe actif
WO2019194358A1 (fr) Composition, comprenant un extrait de plante médicinale ou une fraction correspondante, destinée à la prévention ou au traitement d'une infection par le virus de la grippe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15860435

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15860435

Country of ref document: EP

Kind code of ref document: A1